Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nirmatrelvir plus ritonavir in COVID-19: a profile of its use
Hannah A. Blair
Drugs & Therapy Perspectives (2022) Vol. 39, Iss. 2, pp. 41-47
Open Access | Times Cited: 11

Showing 11 citing articles:

Cholesterol and COVID-19—therapeutic opportunities at the host/virus interface during cell entry
Thomas Grewal, Mai Khanh Linh Nguyen, Christa Buechler
Life Science Alliance (2024) Vol. 7, Iss. 5, pp. e202302453-e202302453
Open Access | Times Cited: 8
Computer-aided drug design of novel nirmatrelvir analogs inhibiting main protease of Coronavirus SARS-CoV-2
Kateryna Lohachova, Anastasiia S . Sviatenko, Alexander Kyrychenko, et al.
Journal of Applied Pharmaceutical Science (2024)
Open Access | Times Cited: 6
Cost‐Effectiveness of Nirmatrelvir/Ritonavir in COVID‐19 Patients at High‐Risk for Progression in Spain
José Ramón Azanza Perea, Juan González del Castillo, R Germán Ferrando, et al.
Journal of Medical Virology (2025) Vol. 97, Iss. 3
Open Access
Main and papain-like proteases as prospective targets for pharmacological treatment of coronavirus SARS-CoV-2
Larysa V. Yevsieieva, Kateryna Lohachova, Alexander Kyrychenko, et al.
RSC Advances (2023) Vol. 13, Iss. 50, pp. 35500-35524
Open Access | Times Cited: 9
Review: The Landscape of Antiviral Therapy for COVID-19 in the Era of Widespread Population Immunity and Omicron-Lineage Viruses
Eric A. Meyerowitz, Yijia Li
Clinical Infectious Diseases (2023) Vol. 78, Iss. 4, pp. 908-917
Open Access | Times Cited: 8
Population Pharmacokinetics of Nirmatrelvir in Chinese Patients with COVID-19: Therapeutic Drug Monitoring and Dosing Regimen Selection in Clinical Practice
Ping Yang, Wei Liu, Yingqiu Ying, et al.
International Journal of Antimicrobial Agents (2024) Vol. 64, Iss. 2, pp. 107199-107199
Closed Access | Times Cited: 2
Drug-drug interactions between COVID-19 drug therapies and antidepressants
Efstathia Davoutis, C Panou, Nikolina Stachika, et al.
Expert Opinion on Drug Metabolism & Toxicology (2023) Vol. 19, Iss. 12, pp. 937-950
Closed Access | Times Cited: 3
Chinese herbal medicine Shufeng Jiedu capsule for mild to moderate COVID-19: a multicenter, randomized, double-blind, placebo-controlled phase II trial
Chun-li Lu, Liuqing Yang, Xin-yan Jin, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Integrated Surveillance of Disparities in Vaccination Coverage and Morbidity during the COVID-19 Pandemic: A Cohort Study in Southeast Sweden
Armin Sprečo, Örjan Dahlström, Dennis Nordvall, et al.
Vaccines (2024) Vol. 12, Iss. 7, pp. 763-763
Open Access
Perfil de seguridad de Paxlovid® contra SARS-CoV2 en pacientes de un hospital en México
Belem Arieth Chan Canche, Abraham Arcos-Díaz, Kyra Angélica Argáez-Ojeda, et al.
Ars Pharmaceutica (Internet) (2024) Vol. 65, Iss. 4, pp. 295-306
Open Access
Nirmatrelvir/ritonavir use in patients with COVID-19 on hemodialysis: a case series
Aihua Zhang, Zong-li Diao, Gang Wang, et al.
Diagnostic Microbiology and Infectious Disease (2023) Vol. 107, Iss. 3, pp. 115969-115969
Open Access | Times Cited: 1
Findings from a discontinued clinical trial of favipiravir in high-risk patients with early-onset COVID-19
Satoshi Iwata, Osamu Kobayashi, Kazuyoshi Kurashima, et al.
Journal of Infection and Chemotherapy (2023) Vol. 30, Iss. 3, pp. 219-227
Open Access | Times Cited: 1
Page 1

Scroll to top